About Us

Biocytogen: One-stop Solution from Target to IND Application

Biocytogen provides one-stop solution for next-generation drug development, from target to IND application to the global biomedical communities. Empowered by its cutting-edge gene editing technologies and state-of-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery. The technical teams in Bicytogen support a comprehensive portfolio of products and services, covering in vivo/in vitro preclinical services, animal model generation, fully human antibody (via RenMab™ Mouse), therapeutic antibody discovery and development services, CMC/CDMO, and regulatory affairs support. Biocytogen collaborates with more than 70% of top 50 pharmaceutical and numerous biotech start-up companies worldwide. Together, we discover innovative medicines for a better, healthier world.

Our Missions

  • Advance life sciences with high-quality and customized models to push the boundary of utilization of humanized target models in biomedical research
  • Develops technological platforms to significantly shorten the next-generation drug discovery and development process
  • Empower scientists in drug discovery by providing the necessary expertise to unstuck bottlenecks in research
  • Be a global leader in all-round preclinical services with unique value propositions to the clients

A central neural circuit for itch sensation

Abstract Although itch sensation is an important protective mechanism for animals, chronic itch remains a challenging clinical problem. Itch processing has been studied extensively at the spinal level. However, how…

Read More

Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection

Abstract During chronic viral infection, virus-specific CD8+ T cells become exhausted, exhibit poor effector function and lose memory potential1,2,3,4. However, exhausted CD8+ T cells can still contain viral replication in chronic infections5,6,7,8,9,…

Read More
Back to top